Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II open-label study of cadonilimab or ivonescimab plus TT-00420 in advanced hepatocellular carcinoma
CTR20252469Phase 2Active
- Sponsor
- TransThera Biosciences
- Start
- Sep 2025
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of tinengotinib, cadonilimab, ivonescimab in hepatocellular carcinoma (HCC), sponsored by TransThera Biosciences. Started Sep 2025; status: active.
02
Drugs
tinengotinibcadonilimabivonescimab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on CTR20252469.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20252469.